Haleos Labs is a pharmaceutical manufacturer that makes the active ingredients inside medicines - the molecules that actually treat the disease - rather than the finished pills. It was carved out of SMS Pharmaceuticals in 2017, but its roots go back to 1990, when it began making Ranitidine HCL, the anti-ulcer drug it still builds its reputation on today. The recurring approach is simple: pick a molecule, master its chemistry to make it cheaper and cleaner than rivals, then use that process know-how to win long-term supply contracts from generic drug companies around the world.
Business segments
A single engine - making bulk drug ingredients and their chemical building blocks - that serves generic pharmaceutical companies across India and export markets, with a small contract manufacturing sideline run on the same factory floors.
1. API and intermediate manufacturing: the molecule factory
The company makes the active chemical ingredients that go into common generic medicines - mostly anti-ulcer drugs - and sells them by the tonne to formulation companies that turn them into tablets.
- One molecule dominates the business - Ranitidine HCL, an anti-ulcer drug the company has made since 1990, contributed just over a third of gross sales in FY22, and the company claims to be one of the single largest manufacturers of it worldwide, with capacity of 2,400 tonnes a year.
- A focused portfolio with deep customer ties - the company makes more than 12 APIs, with the top 10 products accounting for 92% of the portfolio, and its top five clients have been buying from it for an average of 17 years, including names like Mylan, Sun Pharma, and Cadila.
- Sold before it ships, mostly at home - revenue is recognised when control of the goods passes to the customer, typically on shipment or delivery, and in FY25 domestic buyers took roughly 59% of sales, with exports at about 39%.
- Contract manufacturing fills the tanks - alongside its own APIs, the company runs contract manufacturing and custom synthesis projects on the same equipment, including critical intermediate supply work for large US-based customers.
- China sets the price floor - Chinese manufacturers enjoy a 25-30% cost advantage through sheer scale, so the company competes on process efficiency, regulatory approvals, and the "China plus one" shift in pharmaceutical supply chains.
Manufacturing and regulatory backbone
Two factories in Hyderabad plus a subsidiary plant on the Andhra coast give the company 1,013 kilolitres of reactor capacity, all wrapped in USFDA, Japanese, and WHO quality approvals that open doors in regulated markets.
- Three sites, one production philosophy - the main Kazipally and Jeedimetla units in Hyderabad hold a combined 800 KL of capacity, while the Mahi Drugs subsidiary in Anakapalli adds another 213 KL across two API lines and four intermediate blocks, with the ability to run reactions from -70°C to 220°C and pull vacuum down to 0.1 Torr.
- Regulatory licences are the real moat - the facilities carry accreditations from the USFDA, Japan's PMDA, and WHO GMP, and the Kazipally unit received a Voluntary Action Indicated (VAI) status from the USFDA after a May 2025 inspection, meaning no enforcement action was needed.
- Chemistry refined over decades - the in-house R&D unit in Sanath Nagar, recognised by India's DSIR, employs 72 people including two PhD scientists and filed seven USFDA Drug Master Files in FY25 alone, while the manufacturing process for Ranitidine was cut from seven stages to four.
Group structure and partners
The company is a publicly listed manufacturer with a strategically important subsidiary part-owned by its largest American customer, creating a locked-in route to the US generics market.
- Born from a split - Haleos Labs was demerged from SMS Pharmaceuticals Limited in 2017, having previously been its wholly owned subsidiary, and changed its name from SMS Lifesciences to Haleos Labs in August 2025.
- The American partner owns a piece of the factory - ChemWerth Inc., a Connecticut-based generic drug development and supply company, bought a 40% stake in the Mahi Drugs subsidiary in 2022 for about ₹45 crore, leaving Haleos with 60% and creating a direct pipeline into regulated markets.
- A new collaboration targets rare diseases - in January 2026, the company signed a development agreement with HRV Global Life Sciences to accelerate manufacturing of orphan drug and niche therapeutic APIs for the US, EU, Latin America, MENA, and APAC markets, combining Haleos's USFDA-compliant production with HRV's regulatory reach.
- Promoter-led with a seven-person board - the board includes three executive and four independent directors, two of whom are women, while the promoters - Mr. TVVSN Murthy, Mr. TV Praveen, and Mrs. Sudeepthi Gopineedi - are related to each other.